# Dedicated Drug-Drug Interaction (DDI) Study in Healthy Volunteers

> **NCT04939467** · PHASE1 · COMPLETED · sponsor: **Blade Therapeutics** · enrollment: 86 (actual)

## Conditions studied

- Drug Drug Interaction

## Interventions

- **DRUG:** Pirfenidone 267 mg Oral Tablet
- **DRUG:** Nintedanib 150 mg Oral Capsule
- **DRUG:** BLD-0409 750 mg Oral Tablet

## Key facts

- **NCT ID:** NCT04939467
- **Lead sponsor:** Blade Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-10-15
- **Primary completion:** 2021-12-16
- **Final completion:** 2022-04-01
- **Target enrollment:** 86 (ACTUAL)
- **Last updated:** 2022-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04939467

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04939467, "Dedicated Drug-Drug Interaction (DDI) Study in Healthy Volunteers". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT04939467. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*